Lee Jeong Won, Lee Jong Hoon, Kim Jun-Gi, Oh Seong Taek, Chung Hyuk Jun, Lee Myung Ah, Chun Hoo Geun, Jeong Song Mi, Yoon Sei Chul, Jang Hong Seok
Department of Radiation Oncology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
Radiat Oncol J. 2013 Sep;31(3):155-61. doi: 10.3857/roj.2013.31.3.155. Epub 2013 Sep 30.
To evaluate the treatment outcomes of preoperative versus postoperative concurrent chemoradiotherapy (CRT) on locally advanced rectal cancer.
Medical data of 114 patients with locally advanced rectal cancer treated with CRT preoperatively (54 patients) or postoperatively (60 patients) from June 2003 to April 2011 was analyzed retrospectively. 5-Fluorouracil (5-FU) or a precursor of 5-FU-based concurrent CRT (median, 50.4 Gy) and total mesorectal excision were conducted for all patients. The median follow-up duration was 43 months (range, 16 to 118 months). The primary end point was disease-free survival (DFS). The secondary end points were overall survival (OS), locoregional control, toxicity, and sphincter preservation rate.
The 5-year DFS rate was 72.1% and 48.6% for the preoperative and postoperative CRT group, respectively (p = 0.05, the univariate analysis; p = 0.10, the multivariate analysis). The 5-year OS rate was not significantly different between the groups (76.2% vs. 69.0%, p = 0.23). The 5-year locoregional control rate was 85.2% and 84.7% for the preoperative and postoperative CRT groups (p = 0.98). The sphincter preservation rate of low-lying tumor showed significant difference between both groups (58.1% vs. 25.0%, p = 0.02). Pathologic tumor and nodal down-classification occurred after the preoperative CRT (53.7% and 77.8%, both p < 0.001). Acute and chronic toxicities were not significantly different between both groups (p = 0.10 and p = 0.62, respectively).
The results confirm that preoperative CRT can be advantageous for improving down-classification rate and the sphincter preservation rate of low-lying tumor in rectal cancer.
评估术前与术后同步放化疗(CRT)治疗局部晚期直肠癌的疗效。
回顾性分析2003年6月至2011年4月期间114例接受术前(54例)或术后(60例)CRT治疗的局部晚期直肠癌患者的医疗数据。所有患者均接受5-氟尿嘧啶(5-FU)或基于5-FU的同步CRT(中位剂量,50.4 Gy)及全直肠系膜切除术。中位随访时间为43个月(范围,16至118个月)。主要终点为无病生存期(DFS)。次要终点为总生存期(OS)、局部区域控制、毒性反应及保肛率。
术前CRT组和术后CRT组的5年DFS率分别为72.1%和48.6%(单因素分析p = 0.05;多因素分析p = 0.10)。两组的5年OS率无显著差异(76.2%对69.0%,p = 0.23)。术前CRT组和术后CRT组的5年局部区域控制率分别为85.2%和84.7%(p = 0.98)。低位肿瘤的保肛率在两组间有显著差异(58.1%对25.0%,p = 0.02)。术前CRT后病理肿瘤降期和淋巴结降期发生率分别为53.7%和77.8%(均p < 0.001)。两组的急性和慢性毒性反应无显著差异(分别为p = 0.10和p = 0.62)。
结果证实术前CRT有利于提高直肠癌低位肿瘤的降期率和保肛率。